GSK, Theravance commence late-stage clinical trial
LONDON GlaxoSmithKline and Theravance have started a late-stage clinical trial of a drug for treating chronic obstructive pulmonary disorder, GSK announced.
The British drug maker said the first patient had begun treatment as part of a phase 3 trial of a combination between fluticasone furoate and the investigational drug 642444, which belongs to the class known as long-acting beta agonists. GSK markets fluticasone furoate under the brand name Veramyst as a treatment for allergies.
The study will involve more than 6,000 patients and includes two 12-month exacerbation studies, two six-month safety and efficacy studies and others.
Pleio’s medication adherence program yields positive results
PHILADELPHIA A company that runs a medication adherence program said its program had a “highly significant” effect.
Pleio Health Support Systems announced Monday results of the Pleio GoodStart program, analyzing data from 1,776 patients taking a chronic cardiovascular medication between May 2008 and 2009 that showed patients refilled an average of two additional 30-day prescriptions during their initial nine-month period of taking the medication.
Patients in the GoodStart program also refilled their prescriptions an average of 10 days sooner than those in the control group, Pleio said.
Deloitte report: Pharmaceutical companies’ ‘patent cliff’ could bolster mergers, acquisitions
NEW YORK A wave of acquisitions indicates a trend of consolidation in the drug industry, as companies seek ways to build up their research and development pipelines while reducing overhead costs, according to a report released Tuesday by professional services firm Deloitte.
One of the factors driving mergers is that drugs representing more than $74 billion in sales will lose patent protection by 2012, which many analysts have come to call the “patent cliff.”
“With so many rapidly changing dynamics – the patent cliff, healthcare reform and still-dry capital markets – the trends in life sciences industry consolidation are almost certain to continue with a growing emphasis on those deals with companies involved with late-stage developed compounds,” Deloitte & Touche partner Phil Pfrang said in a statement. “Healthy companies have good cause to pursue deals that promise faster revenue streams and profits.”